Volume 32, Issue 11 (Februery 2022)                   Studies in Medical Sciences 2022, 32(11): 824-830 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://umj.umsu.ac.ir/article-1-5408-en.html
Resident of Rheumatology, Department of Internal Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran (Corresponding Author) , Akhlaghimd@yahoo.com
Abstract:   (812 Views)
Background & Aims: Rheumatoid disease is a systemic inflammatory disease with an unknown cause that in addition to joint involvement can have extra-articular manifestations with involvement of any organ. The presence of extra-articular manifestations is associated with poor prognosis and increased mortality. Risk factors for rheumatoid vasculitis include the duration of disease, the presence of rheumatoid nodules, smoking, RF with high titers, and genetic predisposition. Given that no study in Iran has analyzed the prevalence of rheumatoid vasculitis and its risk factors and the fact that the incidence of the disease can be controlled by understanding the changeable risk factors, this study was conducted.
Materials & Methods: 460 patients with rheumatoid arthritis were studied and individuals with rheumatoid vasculitis were identified. Both groups were examined and analyzed in terms of sex, smoking, rheumatoid nodules, RF antibodies, and Anti CCP. Their relationship was assessed by Fisher's exact test or Ka-score. In addition, vasculitis group was evaluated for disease activity based on DAS-28 and acute phase reactants.
Results: Out of 460 patients, 6 patients (1.3%) had rheumatoid vasculitis (3 males and 3 females). The mean duration of the disease at the time of vasculitis was 12.83 years. Of these 6 patients, 3 had mononeuritis multiplex (50%), 2 had scleritis (33%), and one had cutaneous vasculitis (16.6%). None of the patients had subcutaneous nodules. One patient was smoker (16.7%). The mean ESR in vasculitis subjects was 63.16 mm / h and the mean CRP was 37.0 mg / L. Anti CCP antibody was positive in 4 patients (80%) and negative in one patient. RF antibody was positive in 5 patients (100%) and one was not registered. The mean disease activity based on DAS-28 in 4 patients out of 6 patients was 3.73.
Conclusion: In this study, the prevalence of rheumatoid vasculitis was estimated to be 1.3% and there was no statistically significant relationship between rheumatoid vasculitis and the presence of rheumatoid nodules, smoking, RF autoantibodies and Anti CCP. This result could be due to the low volume of the sample in the vasculitis group.
Full-Text [PDF 421 kb]   (390 Downloads)    
Type of Study: Research | Subject: روماتولوژی

1. Watts RA, Mooney J, Lane SE, Scott DG. Rheumatoid vasculitis: becoming extinct? Rheumatology 2004;43(7): 920-3. [DOI:10.1093/rheumatology/keh210] [PMID]
2. Moura MC, Zakszewski PT, Silva MB, Skare TL. Epidemiological profile of patients with extra-articular manifestations of rheumatoid arthritis from the city of Curitiba, south of Brazil. Rev Bras Reumatol 2012;52(5): 679-94. [DOI:10.1590/S0482-50042012000500004]
3. Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. Kelley and Firestein's textbook of rheumatology. Elsevier Health Sciences; 2016. [Google Book]
4. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, Gravallese EM, editors. Rheumatology. 7th edition. Elsevier; 2018. 6189 p. [URL]
5. Davatchi F, Sandoughi M, Moghimi N, Jamshidi AR, Tehrani Banihashemi A, Zakeri Z, et al. Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. Int J Rheum Dis 2016; 19: 1056-62 [DOI:10.1111/1756-185X.12809] [PMID]
6. Jamshidi AR, Tehrani Banihashemi A, Roknsharifi Masoumeh Akhlaghi SH, Salimzadeh A, Davatchi F. Estimating the prevalence and disease characteristics of rheumatoid arthritis in Tehran: A WHO -ILAR COPCORD Study (from Iran COPCORD study, Urban Study stage 1). MJIRI 2013; 28: 9. [URL]
7. Ntatsaki E, Mooney J, Scott DG, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology 2014;53: 145-52. [DOI:10.1093/rheumatology/ket326] [PMID]
8. Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol 2009; 21: 35- 40. [DOI:10.1097/BOR.0b013e32831c5303] [PMID]
9. Anwar MM, Tariq EF, Khan U, Zaheer M, Ijaz SH. Rheumatoid Vasculitis: Is It Always a Late Manifestation of Rheumatoid Arthritis? Cureus 2019; 11(9): e5790. [DOI:10.7759/cureus.5790]
10. Bély M, Apáthy Á. Diagnosis of Systemic Vasculitis of Autoimmune Origin in Rheumatoid Arthritis: Biopsy of Skeletal Muscle in Combination with Sural Nerve is Optimal - A Postmortem Clinicopathologic Study of 161 Patients. EC Cardiology 2018;5: 17-25. [Google Scholar]
11. Bartels C, Bell C, Rosenthal A, Shinki K, Bridges A. Decline in Rheumatoid Vasculitis Prevalence Among US Veterans. Arthritis Rheum 2009;60(9): 2553-7. [DOI:10.1002/art.24775] [PMID] [PMCID]
12. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F. Extra-articular manifestations of rheumatoid arthritis: An update. Autoimmun Rev 2011;11(2): 123-31. [DOI:10.1016/j.autrev.2011.09.001] [PMID]
13. Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a casecontrol study. Rheumatology 2014;53: 890-9. [DOI:10.1093/rheumatology/ket475] [PMID] [PMCID]
14. Ramos M, Mandybur TI. Cerebral Vasculitis in Rheumatoid Arthritis.Arch Neurol1975; 32(4): 271-5. [DOI:10.1001/archneur.1975.00490460087014] [PMID]
15. Bely M, Apathy A. Systemic Vasculitis in Various Organs of 33 Rheumatoid Arthritis and 11 Progressive Systemic Sclerosis Patients - A Comparative Postmortem Study. J Clin Trial Cardiol 2015; 2(2): 1-9. [DOI:10.15226/2374-6882/2/2/00120]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb